EUVIMEDEUVIMED entdecken
Multizentrische StudieKlinische Studie (Phase II)Klinische Studie (Phase I)

All-Oral Treatment of Newly Diagnosed Acute Myeloid Leukemia

Gail J Roboz, Amer M Zeidan, Gabriel N Mannis, Pau Montesinos, Montserrat Arnan, Michael R Savona, Olatoyosi Odenike, James K McCloskey, Harshad V Amin, Amir T Fathi, Teresa Bernal Del Castillo, Gabriela Rodríguez-Macías und 11 weitere

New England Journal of Medicine · 04.06.2026 · 394 (21) · 2107-2116

DOI: 10.1056/nejmoa2510223 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift New England Journal of Medicine, erschienen am 04.06.2026. Verfasst von Gail J Roboz und 22 weiteren Autor:innen. Beteiligte Einrichtung: Weill Cornell Medicine, New York Presbyterian Hospital, New York. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Bridged Bicyclo Compounds, Heterocyclic, Decitabine, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: Taiho Oncology, Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsBridged Bicyclo Compounds, HeterocyclicDecitabineLeukemia, Myeloid, AcuteSulfonamidesUridineAgedAged, 80 and overFemaleHumansMaleAdministration, OralDrug InteractionsArea Under CurveMiddle AgedAnemiaChemotherapy-Induced Febrile NeutropeniaSurvival Analysis

Substanzen

Bridged Bicyclo Compounds, HeterocycliccedazuridineDecitabineSulfonamidesUridinevenetoclax

Autor:innen und Institutionen

  • Weill Cornell Medicine, New York Presbyterian Hospital, New York.
  • Yale University and Yale Comprehensive Cancer Center, New Haven, CT.
  • Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA.
  • Hospital Universitari i Politecnic La Fe, Valencia, Spain.
  • Institut Català d'Oncologia, L'Hospitalet de Llobregat, Institut d'Investigació Biomèdica de Bellvitge, Universitat de Barcelona, Barcelona.
  • Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville.

Förderung

  • Taiho Oncology, Inc

Zitieren

APA

Roboz, G. J., Zeidan, A. M., Mannis, G. N., Montesinos, P., Arnan, M., Savona, M. R., Odenike, O., McCloskey, J. K., Amin, H. V., Fathi, A. T., Bernal Del Castillo, T., Rodríguez-Macías, G., Liesveld, J. L., Im, A. P., Cerny, J., Gentile, T. C., Oganesian, A., Chan, D., Wan, Y., …, & DiNardo, C. D. (2026). All-Oral Treatment of Newly Diagnosed Acute Myeloid Leukemia. New England Journal of Medicine, 394(21), 2107-2116. https://doi.org/10.1056/nejmoa2510223

Vancouver

Roboz GJ, Zeidan AM, Mannis GN, Montesinos P, Arnan M, Savona MR, et al. All-Oral Treatment of Newly Diagnosed Acute Myeloid Leukemia. New England Journal of Medicine. 2026;394(21):2107-2116. doi:10.1056/nejmoa2510223

BibTeX
@article{Roboz2026,
  author = {Roboz, Gail J and Zeidan, Amer M and Mannis, Gabriel N and Montesinos, Pau and Arnan, Montserrat and Savona, Michael R and Odenike, Olatoyosi and McCloskey, James K and Amin, Harshad V and Fathi, Amir T and Bernal Del Castillo, Teresa and Rodríguez-Macías, Gabriela and Liesveld, Jane L and Im, Annie P and Cerny, Jan and Gentile, Teresa C and Oganesian, Aram and Chan, Danna and Wan, Yubing and Dijkstra, Margit and Keer, Harold N and Griffiths, Elizabeth A and DiNardo, Courtney D},
  title = {All-Oral Treatment of Newly Diagnosed Acute Myeloid Leukemia},
  journal = {New England Journal of Medicine},
  year = {2026},
  volume = {394},
  number = {21},
  pages = {2107--2116},
  doi = {10.1056/nejmoa2510223}
}
Kostenlos starten →